Copertina

Applying Cachexia Criteria to Cirrhosis: Considerations for Appropriate Interpretation and Future Research

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autore principale:	Atsushi Nakamura
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Hepatology Research
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Is Glucose Intolerance a Precursor of Cachexia in Patients With Liver Cirrhosis?
di: Tsutomu Nishida, et al.
Pubblicazione: (2025)

Cachexia in Cirrhosis Is Characterized by Sex‐Specific Loss of Muscle Mass and Adipose Tissue
di: Takao Miwa, et al.
Pubblicazione: (2025)

Cachexia and Type 2 Diabetes Mellitus Are Independent Factors for Mortality in Patients With Cirrhosis
di: Takao Miwa, et al.
Pubblicazione: (2025)

Cachexia is an independent predictor of mortality in patients with cirrhosis
di: Takao Miwa, et al.
Pubblicazione: (2025)

Correlations Between Serum Bile Acids and Ammonia Levels in Patients With Cirrhosis
di: Takao Miwa, et al.
Pubblicazione: (2025)

Clinical Utility of the aMAP Risk Score for Predicting the Recurrence of Hepatic Encephalopathy After Rifaximin Treatment in Patients With Liver Cirrhosis: A Retrospective Cohort Study
di: Satoshi Takakusagi, et al.
Pubblicazione: (2026)

Comment on “Using Serum Creatinine‐to‐Cystatin C Ratio to Predict Sarcopenia in Patients With Liver Cirrhosis”
di: Weiming Wang, et al.
Pubblicazione: (2026)

Long‐Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus‐Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study
di: Satoru Kakizaki, et al.
Pubblicazione: (2026)

Altered Serum Bile Acid Pattern as an Independent Factor for Covert and Overt Hepatic Encephalopathy in Patients With Cirrhosis
di: Takao Miwa, et al.
Pubblicazione: (2025)

Obesity Decreases Liver‐Related Death in Patients With Cirrhosis: A Retrospective Propensity Score‐Matched Study
di: Kei Endo, et al.
Pubblicazione: (2025)

ALDH2 Polymorphism in Alcohol‐Related Cirrhosis Requiring Liver Transplantation: A Recipient–Donor Analysis
di: Noriyo Yamashiki, et al.
Pubblicazione: (2026)

Letter to the Editor: “Altered Serum Bile Acid Pattern as an Independent Factor for Covert and Overt Hepatic Encephalopathy in Patients With Cirrhosis”
di: Yumin Guo, et al.
Pubblicazione: (2025)

Animal Naming Test Can Identify Covert Hepatic Encephalopathy in Patients With Cirrhosis With Limited Influence From Age or Educational Level
di: Takao Miwa, et al.
Pubblicazione: (2025)

Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy
di: Nobuaki Ishihara, et al.
Pubblicazione: (2025)

Significance of Evaluating Tumor Markers in the Oncological Criteria for Resectability in Hepatocellular Carcinoma
di: Yuya Miura, et al.
Pubblicazione: (2025)

Do Patients With Alcoholic Cirrhosis Accurately Recognize Their Alcohol Tolerance? A Study Comparing Self‐Perception and ALDH2/ADH1B Genotype
di: Tomoko Tadokoro, et al.
Pubblicazione: (2025)

Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination
di: Yuta Myojin, et al.
Pubblicazione: (2025)

Biopsy‐Proven Reversal of F4 Cirrhosis in Classic Hepatic Glycogen Storage Disease Type IV: A 42‐Year Follow‐Up Without Transplantation
di: Masaaki Mino, et al.
Pubblicazione: (2025)

Clinical Impact of Recurrence Beyond the Milan Criteria After Curative Resection of Hepatocellular Carcinoma
di: Takeshi Terashima, et al.
Pubblicazione: (2025)

Successful Retreatment of Glecaprevir‐Pibrentasvir for Hepatitis C Virus Genotype 2a Infection in Patient Whose Cirrhosis Improved From Decompensation to Compensation After Sofosbuvir–Velpatasvir Therapy
di: Tatsuo Kanda, et al.
Pubblicazione: (2025)

Epidemiology of Fontan‐associated liver disease in Japan: Results from a nationwide survey in 2021
di: Satoko Ohfuji, et al.
Pubblicazione: (2024)

Evaluation of diagnostic criteria for mild‐to‐advanced stages of Fontan‐associated liver disease: A nationwide epidemiological survey in Japan
di: Tomomi Kogiso, et al.
Pubblicazione: (2024)

Impact of muscle volume changes following atezolizumab‐bevacizumab therapy in patients with unresectable hepatocellular carcinoma
di: Hironori Ochi, et al.
Pubblicazione: (2025)

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan
di: Yutaka Handa, et al.
Pubblicazione: (2026)

Clinical Characteristics and Long‐Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd‐Generation Nationwide Survey
di: Yuki Kugiyama, et al.
Pubblicazione: (2025)

Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan
di: Yasue Takeuchi, et al.
Pubblicazione: (2024)

RECAM‐J 2023—Validation and development of the Japanese version of RECAM for the diagnosis of drug‐induced liver injury
di: Atsushi Tanaka, et al.
Pubblicazione: (2024)

Fibrosis‐4 Index as a Robust Long‐Term Predictor of Cancers in Metabolic Dysfunction–Associated Steatotic Liver Disease
di: Ayumi Kanamoto, et al.
Pubblicazione: (2026)

Utilizing Altmetrics to Track Advancements in Noninvasive Tests for MASLD
di: Masato Yoneda, et al.
Pubblicazione: (2025)

Validation of PBC‐10 in Japanese patients with primary biliary cholangitis
di: Akihito Takeuchi, et al.
Pubblicazione: (2025)

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
di: Keishi Ouchi, et al.
Pubblicazione: (2026)

Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
di: Tomomitsu Matono, et al.
Pubblicazione: (2025)

Development of Simplified Risk Assessment Scoring System for Sarcopenia in Patients With Chronic Liver Disease
di: Atsushi Hiraoka, et al.
Pubblicazione: (2025)

Persistent acute kidney injury: Postoperative impact and predictors in patients undergoing liver resection
di: Shunsuke Doi, et al.
Pubblicazione: (2024)

Subcutaneous Adipose Tissue Accumulation is Associated With an Improved Prognosis in Patients With Hepatocellular Carcinoma
di: Kenji Imai, et al.
Pubblicazione: (2026)

Response to “Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma”
di: Kenji Imai, et al.
Pubblicazione: (2026)

Real‐world efficacy of radiomics versus clinical predictors for microvascular invasion in patients with hepatocellular carcinoma: Large cohort study
di: Shotaro Kinoshita, et al.
Pubblicazione: (2024)

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
di: Tomomitsu Matono, et al.
Pubblicazione: (2025)

Defining advanced lymph node metastasis in intrahepatic cholangiocarcinoma: A multicenter study
di: Makoto Kurimoto, et al.
Pubblicazione: (2025)

Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma
di: Kenji Imai, et al.
Pubblicazione: (2025)